Gene · 5469
Papers2,516
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 2,516
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer. | Cancers (Basel) | 2023 | 36980520 | PubTator, text mining | PubMed |
| Advances in Nucleotide Repeat Expansion Diseases: Transcription Gets in Phase. | Cells | 2023 | 36980167 | PubTator, text mining | PubMed |
| HBXIP blocks myosin-IIA assembly by phosphorylating and interacting with NMHC-IIA in breast cancer metastasis. | Acta Pharm Sin B | 2023 | 36970214 | PubTator, text mining | PubMed |
| A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer. | Front Oncol | 2023 | 36937454 | PubTator, text mining | PubMed |
| Relationship between tumor microbiota transcriptional activity and gene expression in breast cancer. | BMC Cancer | 2023 | 36927310 | PubTator, text mining | PubMed |
| The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors. | Int J Biol Sci | 2023 | 36923930 | PubTator, text mining | PubMed |
| Metabolic pathways of potential miRNA biomarkers derived from liquid biopsy in epithelial ovarian cancer. | Oncol Lett | 2023 | 36909377 | PubTator, text mining | PubMed |
| Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity. | Nat Cancer | 2023 | 36894639 | PubTator, text mining | PubMed |
| Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. | Gut | 2023 | 36889906 | PubTator, text mining | PubMed |
| Correction to 'The role of transcriptional coactivator TRAP220 in myelomonocytic differentiation'. | Genes Cells | 2023 | 36880148 | PubTator, text mining | PubMed |
| LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer. | Cancer Res | 2023 | 36877164 | PubTator, text mining | PubMed |
| Biomolecular condensates: Formation mechanisms, biological functions, and therapeutic targets. | MedComm (2020) | 2023 | 36875159 | PubTator, text mining | PubMed |
| Dendrobium mixture ameliorates type 2 diabetes mellitus with non-alcoholic fatty liver disease through PPAR gamma: An integrated study of bioinformatics analysis and experimental verification. | Front Pharmacol | 2023 | 36874030 | PubTator, text mining | PubMed |
| An autoimmune pleiotropic SNP modulates IRF5 alternative promoter usage through ZBTB3-mediated chromatin looping. | Nat Commun | 2023 | 36869052 | PubTator, text mining | PubMed |
| Phase separation in innate immune response and inflammation-related diseases. | Front Immunol | 2023 | 36860877 | PubTator, text mining | PubMed |
| Fine particulate matter (PM2.5)-induced pulmonary oxidative stress contributes to changes in the plasma lipidome and liver transcriptome in mice. | Toxicol Sci | 2023 | 36857595 | PubTator, text mining | PubMed |
| Comparative Genomics of a Polyvalent Escherichia-Salmonella Phage fp01 and In Silico Analysis of Its Receptor Binding Protein and Conserved Enterobacteriaceae Phage Receptor. | Viruses | 2023 | 36851593 | PubTator, text mining | PubMed |
| Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist. | Int J Mol Sci | 2023 | 36835351 | PubTator, text mining | PubMed |
| Phase Separation: Direct and Indirect Driving Force for High-Order Chromatin Organization. | Genes (Basel) | 2023 | 36833426 | PubTator, text mining | PubMed |
| The Role of Peroxisome Proliferator-Activated Receptors in Preeclampsia. | Cells | 2023 | 36831316 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5469/papers?page=16